Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer
Gespeichert in:
| Titel: | Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer |
|---|---|
| Autoren: | Ürün, Y., Hussain, S.A., Bakouny, Z., Castellano, D., Kılıçkap, S., Morgan, G., Mckay, R.R., Pels, K., Schmidt, A., Doroshow, D.B., Schütz, F., Albiges, L., Lopes, G., Catto, J.W.F., Peters, S., Choueiri, T.K. |
| Quelle: | JCO Glob Oncol Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid JCO Global Oncology, Vol, Iss 6, Pp 1248-1257 (2020) JCO global oncology, vol. 6, pp. 1248-1257 |
| Verlagsinformationen: | American Society of Clinical Oncology (ASCO), 2020. |
| Publikationsjahr: | 2020 |
| Schlagwörter: | Adult, Male, Infectious Disease Transmission, Patient-to-Professional, Clinical Decision-Making, Pneumonia, Viral, Medical Oncology, Infectious Disease Transmission, Professional-to-Patient, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Aged, Betacoronavirus/pathogenicity, Coronavirus Infections/epidemiology, Coronavirus Infections/prevention & control, Coronavirus Infections/transmission, Coronavirus Infections/virology, Female, Humans, Infection Control/methods, Infection Control/standards, Infection Control/statistics & numerical data, Infectious Disease Transmission, Patient-to-Professional/prevention & control, Infectious Disease Transmission, Professional-to-Patient/prevention & control, Medical Oncology/methods, Medical Oncology/standards, Medical Oncology/statistics & numerical data, Middle Aged, Neoplasms/diagnosis, Neoplasms/therapy, Oncologists/statistics & numerical data, Pandemics/prevention & control, Personal Protective Equipment/standards, Personal Protective Equipment/statistics & numerical data, Pneumonia, Viral/epidemiology, Pneumonia, Viral/prevention & control, Pneumonia, Viral/transmission, Pneumonia, Viral/virology, Practice Patterns, Physicians'/standards, Practice Patterns, Physicians'/statistics & numerical data, Surveys and Questionnaires/statistics & numerical data, Telemedicine/statistics & numerical data, Surveys and Questionnaires, Neoplasms, Original Reports, Practice Patterns, Physicians', Pandemics, Personal Protective Equipment, RC254-282, Oncologists, Infection Control, SARS-CoV-2, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, COVID-19, 16. Peace & justice, Telemedicine, 3. Good health, Coronavirus Infections |
| Beschreibung: | PURPOSETo understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.METHODSAn online survey was conducted between March 24 and April 29, 2020.RESULTSA total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist’s decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.CONCLUSIONDecision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic. |
| Publikationsart: | Article Other literature type |
| Dateibeschreibung: | application/pdf |
| Sprache: | English |
| ISSN: | 2687-8941 |
| DOI: | 10.1200/go.20.00300 |
| Zugangs-URL: | https://ascopubs.org/doi/pdfdirect/10.1200/GO.20.00300 https://pubmed.ncbi.nlm.nih.gov/32755479 https://hdl.handle.net/20.500.12530/62466 https://doaj.org/article/10c712e7f144403792a261a26b22e458 https://serval.unil.ch/resource/serval:BIB_8FE7781B5AAE.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_8FE7781B5AAE6 https://serval.unil.ch/notice/serval:BIB_8FE7781B5AAE |
| Rights: | CC BY NC ND CC BY |
| Dokumentencode: | edsair.doi.dedup.....2137a5fdca15b0fdbdc5fccd8a514b7a |
| Datenbank: | OpenAIRE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | PURPOSETo understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.METHODSAn online survey was conducted between March 24 and April 29, 2020.RESULTSA total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist’s decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.CONCLUSIONDecision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic. |
|---|---|
| ISSN: | 26878941 |
| DOI: | 10.1200/go.20.00300 |